US FDA Rebukes Another Sponsor For Touting Investigational Product Based On Subgroup Efficacy

 
• By Sue Sutter
  
Rosy picture
The FDA has issues with CytoDyn's rosy picture of leronlimab efficacy in treating COVID. • Source: Alamy

More from Clinical Trials

More from R&D